Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions

NCT ID: NCT05327673

Last Updated: 2022-04-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-31

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland France on the alloSCT on both patients, their caregivers and the healthcare system. It is organised in 3 working packages (WP).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allogeneic Hematopoietic Stem Cell Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients who accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)

questionnaire

Intervention Type OTHER

* quality of life score: FACT-BMT
* decisional conflict scale
* Discreet Choice Experiment questionnaire

patients who did not accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)

questionnaire

Intervention Type OTHER

* quality of life score: FACT-BMT
* decisional conflict scale
* Discreet Choice Experiment questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

questionnaire

* quality of life score: FACT-BMT
* decisional conflict scale
* Discreet Choice Experiment questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome
* candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ;
* Residing in Reunion Island
* Age \>18 year old;
* who accept or not allogeneic hematopoietic
* Able to complete a questionnaire

Exclusion Criteria

* Opposition to participation and collection of their data
* Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Paoli-Calmettes

OTHER

Sponsor Role collaborator

Centre Hospitalier Universitaire de la Réunion

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de la Réunion

Saint-Pierre, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lucie AUZANNEAU

Role: CONTACT

0262359949 ext. +262

Patricia MARINO

Role: CONTACT

04.91.22.35.02 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lucie AUZANNEAU

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020/CHU/21

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.